CXCL12 and renal carcinoma: As recently reported, CXCL12 favors a pro-metastatic bone marrow niche in multiple myeloma, as well as in solid tumors with propensity to give bone metastases, including gastric, medullary thyroid, lung, prostate, and renal carcinomas (45).